- PID
- 3729913
Immuno-oncology
Request For Quotation
Immuno-oncology
- Certification
-
- Award
-
- Shipping
-
- Payment
-
140+ Global Payments, trusted and secure payment provided by PayVerse.
Learn More
- Quantity
- MOQ : 100 doses
Product Summary
(1) Using cutting-edge adjuvant systems “Lipo-pam™” with activating TLR2 and TLR3 to induce Th1 immune response.
(2) On-going Phase I study in S.Korea with CVI-VZV-001 manufactured in GMP facility.
(3) Promising efficacy for equivalent to or greater than Shingrix™
(4) Excellent safety profile compared to Shingrix™
(5) Global Phase II study planned in Q4 2025.
(6) Open for out-licensing or co-development and investment in WW.
(2) On-going Phase I study in S.Korea with CVI-VZV-001 manufactured in GMP facility.
(3) Promising efficacy for equivalent to or greater than Shingrix™
(4) Excellent safety profile compared to Shingrix™
(5) Global Phase II study planned in Q4 2025.
(6) Open for out-licensing or co-development and investment in WW.
Detailed Description
(1) Using cutting-edge adjuvant systems “Lipo-pam™” with activating TLR2 and TLR3 to induce Th1 immune response.
(2) On-going Phase I study in S.Korea with CVI-VZV-001 manufactured in GMP facility.
(3) Promising efficacy for equivalent to or greater than Shingrix™
(4) Excellent safety profile compared to Shingrix™
(5) Global Phase II study planned in Q4 2025.
(6) Open for out-licensing or co-development and investment in WW.
Keyword
Product Data
Other products of this company
